Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients
/in International Publications, Malignant MelanomaDendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma
/in Gallbladder Cancer, International PublicationsGeneration of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy
/in Dendritic Cells, International Publications, Multiple MyelomaDendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
/in Breast Cancer, Dendritic Cells, International PublicationsDendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells
/in HIV/AIDS, International PublicationsThermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines
/in Hyperthermia, International PublicationsDendritic cell vaccination in medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid CancerCharacterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis
/in Dendritic Cells, International Publications, Soft Tissue SarcomaTransient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer